Ping Li

Ping Li

Auto-generated profile, based on publicly available information

Ping Li

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
URUri Rozovski
Uri Rozovski
DHDavid M. Harris
David M. Harris
PLPing Li
Ping Li
ZLZhiming Liu
Zhiming Liu
JWJi Yuan Wu
Ji Yuan Wu
ZEZeev Estrov
Zeev Estrov
In chronic lymphocytic leukemia (CLL), the increment in PBLs is slower than the expected increment calculated from the cells’ proliferation rate, suggesting that cellular proliferation and apoptosis are concurrent. Exploring this phenomenon, we found overexpression of caspase-3, higher cleaved poly (ADP-ribose) polymerase levels (p < 0.007), and a higher apoptosis rate in cells from patients with high counts compared with cells from patients with low counts. Although we previously found that STAT3 protects CLL cells from apoptosis, STAT3 levels were significantly higher in cells from patients with high counts than in cells from patients with low counts. Furthermore, overexpression of STAT3 did not protect the cells. Rather, it upregulated caspase-3 and induced apoptosis. Remarkably, putative STAT3 binding sites were identified in the caspase-3 promoter, and a luciferase assay, chromatin immunoprecipitation, and an EMSA revealed that STAT3 activated caspase-3. However, caspase-3 levels increased only when STAT3 levels were sufficiently high. Using chromatin immunoprecipitation and EMSA, we found that STAT3 binds with low affinity to the caspase-3 promoter, suggesting that at high levels, STAT3 activates proapoptotic mechanisms and induces apoptosis in CLL cells.

1 December 2019 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
URUri Rozovski
Uri Rozovski
DHDavid M. Harris
David M. Harris
PLPing Li
Ping Li
ZLZhiming Liu
Zhiming Liu
PJPreetesh Jain
Preetesh Jain
ZEZeev Estrov
Zeev Estrov
The wingless and integration site growth factor-5a (Wnt5a) is a ligand of the receptor tyrosine kinase-like orphan receptor-1 (ROR1). Because both Wnt5a and ROR1 are expressed in circulating chronic lymphocytic leukemia (CLL) cells, and because in other cell types, STAT3, which is constitutively activated in CLL, induces Wnt5a signaling, we wondered whether STAT3 induces the expression of Wnt5a in CLL cells. Sequence analysis detected four putative STAT3 binding sites in close proximity to the Wnt5a gene promoter’s start codon. Chromatin immunoprecipitation and EMSA revealed that STAT3 binds to the Wnt5a gene promoter, and a luciferase assay showed that STAT3 activates the Wnt5a gene. Additionally, transfection of peripheral blood CLL cells with STAT3 short hairpin RNA downregulated Wnt5a mRNA and protein levels, suggesting that STAT3 binds to the Wnt5a gene promoter and induces the expression of Wnt5a in CLL cells. Flow cytometry and confocal microscopy determined that both Wnt5a and its receptor ROR1 are coexpressed on the surface of CLL cells, and Western immunoblotting showed an inverse correlation between Wnt5a and ROR1 protein levels, implying that, regardless of CLL cells’ ROR1 levels, blocking the interaction between Wnt5a and ROR1 might be beneficial to patients with CLL. Indeed, transfection of CLL cells with Wnt5a small interfering RNA reduced Wnt5a mRNA and protein levels and significantly increased the spontaneous apoptotic rate of CLL cells. Taken together, our data unravel an autonomous STAT3-driven prosurvival circuit that provides circulating CLL cells with a microenvironment-independent survival advantage.

20 May 2022 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
URUri Rozovski
Uri Rozovski
IVIvo Veletic
Ivo Veletic
DHDavid M. Harris
David M. Harris
PLPing Li
Ping Li
ZLZhiming Liu
Zhiming Liu
ZEZeev Estrov
Zeev Estrov
Pentraxin-related protein 3 (PTX3), commonly produced by myeloid and endothelial cells, is a humoral pattern recognition protein of the innate immune system. Because PTX3 plasma levels of patients with chronic lymphocytic leukemia (CLL) are high and most circulating cells in patients with CLL are CLL cells, we reasoned that CLL cells produce PTX3. Western immunoblotting revealed that low-density cells from seven of seven patients with CLL produce high levels of PTX3, flow cytometry analysis revealed that the PTX3-producing cells are B lymphocytes coexpressing CD19 and CD5, and confocal microscopy showed that PTX3 is present in the cytoplasm of CLL cells. Because STAT3 is constitutively activated in CLL cells, and because we identified putative STAT3 binding sites within the PTX3 gene promoter, we postulated that phosphorylated STAT3 triggers transcriptional activation of PTX3. Immunoprecipitation analysis of CLL cells’ chromatin fragments showed that STAT3 Abs precipitated PTX3 DNA. STAT3 knockdown induced a marked reduction in PTX3 expression, indicating a STAT3-induced transcriptional activation of the PTX3 gene in CLL cells. Using an EMSA, we established and used a dual-reporter luciferase assay to confirm that STAT3 binds the PTX3 gene promoter. Downregulation of PTX3 enhanced apoptosis of CLL cells, suggesting that inhibition of PTX3 might benefit patients with CLL.

3 April 2023
Verified
Other
Open access
URUri Rozovski
Uri Rozovski
SGSrdana Grgurevic
Srdana Grgurevic
CBCarlos Bueso-Ramos
Carlos Bueso-Ramos
DHDavid M. Harris
David M. Harris
PLPing Li
Ping Li
ZEZeev Estrov
Zeev Estrov
Supplemental Table 1. Patient Characteristics

2 November 2023 in Blood
Verified
Journal Article
Open access
IVIvo Veletic
Ivo Veletic
TMTaghi Manshouri
Taghi Manshouri
CPChristopher D. Pacheco
Christopher D. Pacheco
C. Cameron YinC. Cameron Yin
C. Cameron Yin
YZYing Zhang
Ying Zhang
ZEZeev Estrov
Zeev Estrov
Disclosures. Veletic:Avilect Biosciences: Research Funding. Verstovsek:Kartos Therapeutics: Current Employment.